Explore Business Standard
Don’t miss the latest developments in business and finance.
Achieving a 'Bimari Mukt Bharat' or disease-free India is important for realising the goal of 'Viksit Bharat' by 2047, feels social activist and entrepreneur Dr Swapna Verma, who is spearheading a project to deliver tech-enabled diagnostic services at the doorsteps of rural and tribal communities. Verma was among the 10 'pathbreakers' whom Prime Minister Narendra Modi met earlier this month during the Viksit Bharat Young Leaders' Dialogue-2025. Hailing from Satna district in Madhya Pradesh, Verma is the founder of the Madhurima Sewa Sanskar Sansthan. During the young leaders' dialogue at the National Youth Festival, Verma outlined her organisation's flagship project -- 'Heal Rural India' -- before the prime minister, highlighting the scalability of the initiative. Recounting her first meeting with Modi, Verma, who is also part of the Madhya Pradesh BJP unit, said the prime minister asked her how the 'Heal Rural India' project can help make 'Bharat' become 'Bimari Mukt'. "I explain
Genetic defects underlie about a fourth of Chinese children affected by cerebral palsy, and not a lack of oxygen at birth as previously thought, new research has found. Cerebral palsy is a disorder affecting one's ability to move. It is the most common motor disability in children, with symptoms emerging in infancy and early childhood. The disability is sometimes also associated with autism and intellectual deficiencies. Birth asphyxia, or receiving insufficient oxygen at the time of being born, can cause physical harm, especially to the brain, and is considered one of the main causes of cerebral palsy. The world's largest study of cerebral palsy genetics, involving more than 1,500 affected Chinese children, found that mutations were significantly higher in a fourth of these children receiving insufficient oxygen at birth. Researchers said this indicated that birth asphyxia could be secondary to the underlying genetic defects. The results, published in the journal Nature Medicine
India has emerged as a premier destination for conducting global clinical trials, an Indian bureaucrat who is also a Harvard scholar has said, asserting that the pharma industry must recognise the country's intrinsic value as a primary location rather than relegating it to a secondary backup role. Speaking at a recent Bio-Pharma summit in Boston, Dr Mrinalini Darswal, an Indian diplomat who is currently a PhD scholar at Harvard University, said that India "boasts a robust infrastructure, a cadre of seasoned investigators, and cost-effectiveness, collectively rendering it an appealing choice for such endeavours. The present aspirational India under the strong and transformative leadership of our Prime Minister Narendra Modi has emerged as a premier destination for conducting global clinical trials, having streamlined its regulatory framework and elevated its compliance standards to align with international good clinical practices, Darswal said. This starkly contrasts larger economies